Investing.com - G1 Therapeutics (NASDAQ: GTHX) reported third quarter EPS of $-0.35, worse than the analyst estimate of $-0.34. Revenue for the quarter came in at $12.3M versus the consensus estimate of $14.24M.
G1 Therapeutics's stock price closed at $1.65. It is down -23.96% in the last 3 months and down -79.90% in the last 12 months.
G1 Therapeutics saw 5 positive EPS revisions and 0 negative EPS revisions in the last 90 days. See G1 Therapeutics's stock price’s past reactions to earnings here.
According to InvestingPro, G1 Therapeutics's Financial Health score is "good performance".
Check out G1 Therapeutics's recent earnings performance, and G1 Therapeutics's financials here.
Stay up-to-date on all of the upcoming earnings reports by visiting Investing.com's earnings calendar